However, several studies have also found that sulindac demonstrated its anti-tumorigenic activity through inhibition of NF-κB activation and targeting Cox-independent pathways in cancer cells (Li et al., 2012; Lee et al., 2008; Piazza et al., 2009; Sinha et al., 2022). This evidence concerns the gene NFKB1 and cancer.